<DOC>
	<DOCNO>NCT02646267</DOCNO>
	<brief_summary>The purpose trial demonstrate efficacy safety dabigatran etexilate different intensity warfarin prevention stroke systemic embolism patient non-valvular atrial fibrillation .</brief_summary>
	<brief_title>The Efficacy Safety Study Dabigatran Warfarin Non-valvular Atrial Fibrillation Patients</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . Clinical diagnosis atrial fibrillation 2 . Echocardiography confirm nonvalvular heart disease 3 . Ageâ‰¥60 year 1 . Unable cooperate doctor 2 . CHA2DS2VASc &lt; 2 3 . Life expectancy less 1 year 4 . Rheumatic heart disease dilate cardiomyopathy 5 . History artificial valve replacement surgery 6 . Infectious endocarditis 7 . Stroke transient ischemic attack ( TIA ) within last 6 month 8 . Previous history intracranial hemorrhage , gastrointestinal , respiratory urogenital bleeding 9 . Previous intolerance/allergy warfarin dabigatran etexilate 10 . Blood pressure great 180/110 mmHg 11 . Chronic liver dysfunction , alanine aminotransferase normal reference value upper limit 3 time 12 . Chronic renal failure , serum creatinine clearance rate ( Ccr ) less 30 ml / min 13 . Patient receive antiplatelet anticoagulant therapy due reason</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Dabigatran</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Anticoagulation</keyword>
	<keyword>Elderly</keyword>
</DOC>